Wells Fargo lowered the firm’s price target on Ultragenyx (RARE) to $65 from $88 and keeps an Overweight rating on the shares. The firm says that while there is some debate around the update impact on setru’s probability of success, Wells doesn’t expect the peak sales opportunity to materially change if setru is ultimately approved.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Positive Outlook for Ultragenyx Pharmaceutical Amidst Promising Pipeline and Growth Potential
- Optimistic Buy Rating for Ultragenyx Despite Interim Setbacks in Clinical Trials
- Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation
- Ultragenyx Advances Phase 3 Study for UX143 Drug
- Ultragenyx, Mereo BioPharma receive DMC recommendation to continue Orbit study